false
Catalog
The Liver Meeting 2022
Alcohol-associated Liver Disease SIG and Nonalcoho ...
Alcohol-associated Liver Disease SIG and Nonalcoholic Fatty Liver Disease SIG Program: NAFLD and ALD: Similarities, Differences, and Learning Opportunities. PART 1: Mechanisms, Risk Factors and Biomarkers
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discusses non-invasive biomarkers for the diagnosis and prognosis of non-alcoholic fatty liver disease (NAFLD). Dr. Ashwaney Singhal explains the importance of diagnosing advanced fibrosis in NAFLD patients and introduces the FIB-4 test as a first-line screening tool. He also discusses other non-invasive tests such as ELF, NASH-FIB score, APRI, and NAFLD-FIB score. Dr. Singhal emphasizes the need for multiple tests to narrow down the stage of fibrosis. He also discusses the use of non-invasive tests to monitor response to therapy and their correlation with clinical liver events. Dr. Mosenouardine presents a study using machine learning tests to accurately predict fibrosis stages and other liver disease markers. Dr. Nacker-Thiel focuses on non-invasive tests in alcoholic liver disease and highlights the diagnostic accuracy of transient elastography and blood-based tests. Dr. Ali-Etekore discusses the use of proteomics as a promising approach for assessing liver fibrosis and other liver disease markers. The panel discussion addresses questions about non-invasive tests, population-specific cutoffs, and the need for further research. Overall, the video highlights the potential of non-invasive tests and machine learning in assessing liver fibrosis and other liver disease markers, and underscores the need for more research in this field.
Keywords
non-invasive biomarkers
diagnosis
prognosis
NAFLD
advanced fibrosis
FIB-4 test
ELF
NASH-FIB score
APRI
multiple tests
response to therapy
machine learning tests
liver disease markers
×
Please select your language
1
English